Bruker Corporation announced the launch of CellScape XR, a next-generation spatial proteomics platform aimed at supporting diagnostic and prognostic assay development. The company said the platform is designed to deliver improved quantitation, robustness and throughput, and includes advances in optics, fluidics and protocols to support high-throughput and reproducible spatial proteomics. Bruker also cited collaborations using the CellScape platform, including work at University Hospital Schleswig-Holstein, Kiel (UKSH), which has analyzed more than 1,000 clinically annotated samples and plans to extend the study to about 3,000 patient samples.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bruker Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202602250700BIZWIRE_USPR_____20260225_BW450411) on February 25, 2026, and is solely responsible for the information contained therein.